» Articles » PMID: 9405384

Identification of Residues in the Drug-binding Site of Human P-glycoprotein Using a Thiol-reactive Substrate

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1998 Jan 24
PMID 9405384
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

We identified a thiol-reactive compound, dibromobimane (dBBn), that was a potent stimulator (8.2-fold) of the ATPase activity of Cys-less P-glycoprotein. We then used this compound together with cysteine-scanning mutagenesis to identify residues in transmembrane segment (TM) 6 and TM12 that are important for function. TM6 and TM12 lie close to each other in the tertiary structure and are postulated to be important for drug-protein interactions. The majority of P-glycoprotein mutants containing a single cysteine residue retained substantial amounts of drug-stimulated ATPase activity and were not inhibited by dBBn. The ATPase activities of mutants L339C, A342C, L975C, V982C, and A985C, however, were markedly inhibited (>60%) by dBBn. The drug substrates verapamil, vinblastine, and colchicine protected these mutants against inhibition by dBBn, suggesting that these residues are important for interaction of substrates with P-glycoprotein. We previously showed that residues Leu339, Ala342, Leu975, Val982, and Ala985 lie along the point of contact between helices TM6 and TM12, when both are aligned in a left-handed coiled coil (Loo, T. W., and Clarke, D. M. (1997) J. Biol. Chem. 272, 20986-20989). Taken together, these results suggest that the interface between TM6 and TM12 likely forms part of the potential drug-binding pocket in P-glycoprotein.

Citing Articles

Thioxobimanes.

Das P, Roy A, Nandi A, Neogi I, Diskin-Posner Y, Marks V J Org Chem. 2023; 88(19):13475-13489.

PMID: 37712568 PMC: 10563133. DOI: 10.1021/acs.joc.3c00873.


The human proton pump inhibitors inhibit rifampicin efflux and macrophage-induced rifampicin tolerance.

Lake M, Adams K, Nie F, Fowler E, Verma A, Dei S Proc Natl Acad Sci U S A. 2023; 120(7):e2215512120.

PMID: 36763530 PMC: 7614234. DOI: 10.1073/pnas.2215512120.


Target-Agnostic P-Glycoprotein Assessment Yields Strategies to Evade Efflux, Leading to a BRAF Inhibitor with Intracranial Efficacy.

Kelly A, Berry M, Tasker S, McKee S, Fan T, Hergenrother P J Am Chem Soc. 2022; 144(27):12367-12380.

PMID: 35759775 PMC: 9612427. DOI: 10.1021/jacs.2c03944.


Emerging consensus on the mechanism of polyspecific substrate recognition by the multidrug transporter P-glycoprotein.

Xia D, Zhou F, Esser L Cancer Drug Resist. 2022; 2(3):471-489.

PMID: 35582581 PMC: 8992534. DOI: 10.20517/cdr.2019.22.


Extended-ensemble docking to probe dynamic variation of ligand binding sites during large-scale structural changes of proteins.

Kapoor K, Thangapandian S, Tajkhorshid E Chem Sci. 2022; 13(14):4150-4169.

PMID: 35440993 PMC: 8985516. DOI: 10.1039/d2sc00841f.